ADC Therapeutics

/ADC Therapeutics

We are a clinical-stage oncology-focused biotechnology company pioneering the development of highly potent and targeted antibody drug conjugates (“ADCs”) for patients suffering from hematological malignancies and solid tumors.


Price Range
$23.00 - $26.00

Final Shares

Anticipated Date
October 3, 2019


This offering is no longer available

To view the prospectus for IPO, or any offering listed on ClickIPO,
download the ClickIPO app...

or a prospectus can be requested from G. Price at
ClickIPO Securities, LLC P. O. Box 21154, Mesa, AZ 85277

Secured By miniOrange